GDTC
CytoMed Therapeutics Ltd
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.
Market Cap: 24.1 Million
Primary Exchange: NASDAQ
Shares Outstanding: 11.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.4112119387903398
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 184 trading days
From: 2023-07-11 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|